EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Radiotherapy for human T-cell leukemia virus type 1–associated adult T-cell leukemia/lymphoma

Kohei Tokuyama, Takayoshi Itaya, Ayaka Hara, Motoko Tanabe, Shoko Takata, Takashige Kiyota, Tomoko Yamate, Yutaka Hatano, Masao Ogata, Kuniko Takano, Yoshiki Asayama

Journal of Radiation Research · 2025

DOI: 10.1093/jrr/rraf036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Radiation Research, 2025. Verfasst von Kohei Tokuyama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita 879-5593, Japan. Hauptthemen laut MEDLINE: Leukemia-Lymphoma, Adult T-Cell, Human T-lymphotropic virus 1. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adult T-cell lymphoma/leukemia (ATL) is an aggressively malignant peripheral T-cell neoplasm. Only a few studies have reported the use of radiotherapy (RT) for ATL. Therefore, the aim of this study was to clarify the efficacy of RT for ATL. We retrospectively reviewed 90 courses of RT administered to 19 consecutive ATL patients between 2008 and 2023. The subtypes included lymphoma (n = 8), acute (n = 7), smoldering (n = 3) and unknown (n = 1). Ninety lesions (cutaneous = 72, extranodal = 10, nodal = 8) were treated at a mean dose of 39.1 Gy/3.2 Gy (range, 24–60 Gy). Administration of RT for ATL lesions resulted in a combined complete response and partial response rate of 92%. At a mean of 47.5 months of follow-up (range, 0–102 months), local recurrence was not observed in 98.9% of the courses. A treatment response in terms of clinical symptoms was observed in 92% of the courses. The median survival time was 918 days. No acute grade ≥3 toxicity or any late toxicity was noted. In conclusion, RT was confirmed to be effective and safe for the treatment of local ATL lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia-Lymphoma, Adult T-CellHuman T-lymphotropic virus 1HumansMiddle AgedMaleFemaleAgedAdultTreatment OutcomeAged, 80 and overRetrospective Studies

Stichwörter der Autor:innen

adult t-cell leukemia/lymphomacentral nervous systemhuman t-cell leukemia virus type 1radiotherapy

Autor:innen und Institutionen

  • Department of Radiology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita 879-5593, Japan.
  • Department of Radiology, Oita Prefectural Hospital, 476 Bunyo, Oita-shi, Oita 870-8511, Japan.
  • Department of Dermatology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita 879-5593, Japan.
  • Department of Medical Oncology and Hematology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita 879-5593, Japan.
  • Department of Hematology, Oita University Hospital, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita 879-5593, Japan.

Zitieren

APA

Tokuyama, K., Itaya, T., Hara, A., Tanabe, M., Takata, S., Kiyota, T., Yamate, T., Hatano, Y., Ogata, M., Takano, K., & Asayama, Y. (2025). Radiotherapy for human T-cell leukemia virus type 1–associated adult T-cell leukemia/lymphoma. Journal of Radiation Research. https://doi.org/10.1093/jrr/rraf036

Vancouver

Tokuyama K, Itaya T, Hara A, Tanabe M, Takata S, Kiyota T, et al. Radiotherapy for human T-cell leukemia virus type 1–associated adult T-cell leukemia/lymphoma. Journal of Radiation Research. 2025. doi:10.1093/jrr/rraf036

BibTeX
@article{Tokuyama2025,
  author = {Tokuyama, Kohei and Itaya, Takayoshi and Hara, Ayaka and Tanabe, Motoko and Takata, Shoko and Kiyota, Takashige and Yamate, Tomoko and Hatano, Yutaka and Ogata, Masao and Takano, Kuniko and Asayama, Yoshiki},
  title = {Radiotherapy for human T-cell leukemia virus type 1–associated adult T-cell leukemia/lymphoma},
  journal = {Journal of Radiation Research},
  year = {2025},
  doi = {10.1093/jrr/rraf036}
}
Kostenlos starten →